QC
XERS icon

Quadrature Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Quadrature Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,289
Closed -$141K – 1707
2025
Q3 		$141K Sell
17,289
-29,467
-63% -$196K ﹤0.01% 840
2025
Q2 		$219K Buy
46,756
+15,623
+50% +$71.6K ﹤0.01% 790
2025
Q1 		$171K Buy
+31,133
New +$126K ﹤0.01% 877

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Quadrature Capital's XERS Position: Q4 2025 in Review

Quadrature Capital sold out of Xeris Biopharma Holdings (XERS) in Q4 2025, closing a stake of 17,289 shares — an estimated $141K sold.

Quadrature Capital first reported a position in XERS in Q1 2025 and held it in 3 quarters. The position peaked at $219K in Q2 2025. 225 funds tracked by Wall St. Rank hold XERS as of Q4 2025.

  • Quadrature Capital reported no remaining Xeris Biopharma Holdings position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 17,289 Xeris Biopharma Holdings shares in Q4 2025, an estimated $141K.
  • Quadrature Capital first reported a position in Xeris Biopharma Holdings in Q1 2025 and held it in 3 quarters.
  • Quadrature Capital's Xeris Biopharma Holdings position peaked at $219K in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.